Corporate Banner
Satellite Banner
qPCR
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Quest Diagnostics and Hologic Form Strategic Alliance to Improve Women's Health

Published: Tuesday, June 11, 2013
Last Updated: Tuesday, June 11, 2013
Bookmark and Share
Collaboration features national availability of the APTIMA HPV mRNA-based cervical cancer screening test.

Quest Diagnostics and Hologic, Inc. announced that they have entered into a strategic alliance to more broadly offer testing based on Hologic's APTIMA family of products, as well as to co-develop and promote advanced diagnostic solutions to improve women's health.

"This alliance will enhance the ability of Quest Diagnostics to deliver state-of-the-art testing methods and specialized expertise in women's health diagnostic information services," said Steve Rusckowski, President and Chief Executive Officer, Quest Diagnostics. "It builds on our long-standing successful relationship with Hologic to lead the way in delivering solutions that address the clinical challenges facing obstetricians and gynecologists in treating women. This collaboration also promises to increase the range of capabilities for advancing the health of women for both companies."

"This collaboration represents a potentially important new chapter in women's health diagnostics," said Rob Cascella, Hologic's President and Chief Executive Officer. "Quest Diagnostics' strong capabilities in diagnostic information services and laboratory and interpretive consulting, when combined with Hologic's technical expertise and product excellence, holds the potential for us to develop new capabilities for serving unmet clinical needs for women in other areas of cancer detection."

Under a non-exclusive agreement with an initial term of five years, the companies will focus primarily on clinical areas critical to the health of women. Quest Diagnostics will transition to a broader offering of services based on Hologic's APTIMA family of products, which includes FDA-approved or cleared assays for HPV, HPV genotyping, chlamydia, gonorrhea and trichomonas vaginalis. In addition, Quest Diagnostics will continue to utilize Hologic's leading line of ThinPrep liquid-based cytology products.

Quest Diagnostics will also continue to offer Hologic's APTIMA HPV mRNA-based assay nationally. Unlike other FDA-approved, DNA-based HPV tests, the APTIMA HPV assay detects messenger RNA over-expressed from two viral oncogenes that are integral to the development of cervical cancer. Hologic's APTIMA HPV assay detects E6/E7 viral mRNA from 14 high-risk types of human papillomavirus in cervical specimens (refer to package insert for other indications and limitations).

"Most HPV infections clear up on their own, so it's important to identify those persistent, high-risk infections that are most likely to lead to cervical cancer," said Tom Wright, MD, professor emeritus of pathology and cell biology at the Columbia University Medical Center. "In numerous clinical studies involving approximately 45,000 women, the APTIMA HPV mRNA assay has consistently shown similar sensitivity and better specificity than the most frequently used DNA-based test. This means the APTIMA HPV assay is highly accurate in detecting cervical disease, but is less likely to raise false alarms that can result in unnecessary medical procedures."

The companies will also explore opportunities to develop and expand access to new diagnostic solutions for women's health. In addition, they will implement joint programs to advance women's health issues with medical associations and patient advocacy groups and to sponsor research. Financial terms of the collaboration were not disclosed.

"Our relationship with Hologic also demonstrates our progress executing on our restore growth and operational excellence strategies," said Mr. Rusckowski, Quest's CEO. "With this alliance, we will strengthen the specialization and competitiveness of our women's health business. We are also working more closely and strategically with suppliers, and this alliance is the first under our new, highly rigorous supplier engagement model, which we unveiled at our first ever Supplier Forum in March."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
$1M NIH Grant to Refine PCR Based Cancer Test
Researchers at Cornell University, Weill Cornell Medicine, the University of California, San Francisco, and the Infectious Diseases Institute in Kampala, Uganda, recieve a four-year, $1 million grant to hone technology for a quick, in-the-field diagnosis of Kaposi's sarcoma — a cancer frequently related to HIV infections.
Genetic Tug of War Before Cells Decide Fate
Researchers report that as developing blood cells are triggered by genetic signals firing on and off, a 'tug of war' occurs.
Linkage Biosciences Awarded NHS Contract
Comapny announces that it has been awarded a four-year contract by NHS Blood and Transplant (NHSBT) in the UK for implementation of the LinkSeq™ Real-Time PCR HLA typing product.
Understanding Tumor Evolution
Study provides insight into tumor evolution; may point to improved diagnosis and treatment.
Frankfurter Fraud: Finding Out What’s In Your Hot Dog
Scientists have developed a technique to test the meat content of Frankfurters.
How Cloud Connectivity Can Combat the Reproducibility Crisis
This infographic explains the reproducibility crisis, and how cloud connectivity can help overcome this problem.
Keeping Cells in Shape to Fight Sepsis
Boosting levels of a protein that controls the shape and activity of a crucial group of white blood cells improves survival and recovery chances during sepsis.
This 3D Printer Can Detect Infectious Diseases
Researchers at AI Biosciences, Inc. have repurposed 3D printers into machines capable of performing sample preparation and DNA amplification.
Natera, UCSF Announce Collaboration
Joint research program to study DNA markers of kidney transplant rejection.
CDC Updates Zika Recommendations
CDC has issued updated Zika recommendations and guidance for healthcare providers with a focus on sexual transmission.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!